• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

[A case of small cell lung cancer with renal insufficiency effectively treated with oral etoposide administration].

作者信息

Akiyama Y, Kondo H, Kimura S, Fujii Y

机构信息

Dept. of Respiratory Medicine, Komatsushima Red Cross Hospital.

出版信息

Gan To Kagaku Ryoho. 1995 Apr;22(5):683-6.

PMID:7717722
Abstract

A 74-year-old woman with left-sided heart failure was admitted to our department with abnormal shadow in the right lung. Chest X-P and CT scans showed a tumor shadow measuring 2.5 cm in the right lower lobe and mediastinal lymphnode swelling. Cytological examination of needle biopsy specimen revealed small cell carcinoma (cT1N2M0). Elevations of tumor marker, NSE and CEA were noticed at 11.8 and 12.7 ng/ml, respectively. Considering complications including renal insufficiency and heart failure in the case, 2 courses of oral etoposide (25 mg/body) for 21 consecutive days were performed. The tumor shadow decreased remarkably in size and complete response (CR) was obtained. Side effects were all tolerable. A pharmacokinetic study of etoposide revealed serum etoposide levels of more than 1.0 microgram/ml on day 15. These results suggest that oral etoposide administration is an effective regimen in small cell lung cancer patients associated with renal insufficiency.

摘要

相似文献

1
[A case of small cell lung cancer with renal insufficiency effectively treated with oral etoposide administration].
Gan To Kagaku Ryoho. 1995 Apr;22(5):683-6.
2
[An elderly case of small cell lung cancer showing complete response by oral administration of etoposide].[1例口服依托泊苷后完全缓解的老年小细胞肺癌病例]
Gan To Kagaku Ryoho. 1990 Jan;17(1):141-5.
3
[An elderly case of small cell lung cancer showing a good partial response by chronic daily administration of oral etoposide].[1例老年小细胞肺癌患者通过口服依托泊苷长期每日给药显示出良好的部分缓解]
Gan To Kagaku Ryoho. 1991 Jan;18(1):111-4.
4
[Nedaplatin and etoposide combination chemotherapy in a patient with small cell carcinoma undergoing hemodialysis].[奈达铂与依托泊苷联合化疗用于一名接受血液透析的小细胞癌患者]
Gan To Kagaku Ryoho. 1999 Mar;26(4):527-30.
5
Pharmacology of 21-day oral etoposide given in combination with i.v. cisplatin in patients with extensive-stage small cell lung cancer: a cancer and leukemia group B study (CALGB 9062).广泛期小细胞肺癌患者中21天口服依托泊苷联合静脉注射顺铂的药理学:癌症与白血病B组研究(CALGB 9062)
Clin Cancer Res. 1997 May;3(5):719-25.
6
[A case of remission of multiple retroperitoneal lymph node relapse in small cell lung cancer treated with oral etoposide].[口服依托泊苷治疗小细胞肺癌多发腹膜后淋巴结复发缓解 1 例]
Gan To Kagaku Ryoho. 1991 Feb;18(2):297-300.
7
Clinical pharmacology of chronic oral etoposide in patients with small cell and non-small cell lung cancer.口服依托泊苷治疗小细胞和非小细胞肺癌患者的临床药理学
Clin Cancer Res. 1995 Dec;1(12):1517-24.
8
[Successful treatment of refractory extensive small cell lung cancer by oral etoposide].口服依托泊苷成功治疗难治性广泛性小细胞肺癌
Gan To Kagaku Ryoho. 1994 Aug;21(10):1677-80.
9
A Phase I-II study of sequential administration of topotecan and oral etoposide (toposiomerase I and II inhibitors) in the treatment of patients with small cell lung carcinoma.一项关于拓扑替康与口服依托泊苷(拓扑异构酶I和II抑制剂)序贯给药治疗小细胞肺癌患者的I-II期研究。
Cancer. 2002 Oct 1;95(7):1511-9. doi: 10.1002/cncr.10836.
10
[Early phase II study of oral administration of etoposide for 21 consecutive days in patients with non-small-cell lung cancer].[口服依托泊苷连续21天治疗非小细胞肺癌患者的II期早期研究]
Nihon Kyobu Shikkan Gakkai Zasshi. 1995 Dec;33(12):1367-1371.

引用本文的文献

1
Successful treatment of a patient with small cell lung cancer receiving hemodialysis, with concurrent oral etoposide and radiotherapy: A case report.成功治疗一名接受血液透析的小细胞肺癌患者,同时采用口服依托泊苷和放疗:病例报告
Medicine (Baltimore). 2020 Oct 2;99(40):e22637. doi: 10.1097/MD.0000000000022637.